Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients
- 13 September 2011
- Vol. 54 (5), 420-433
- https://doi.org/10.1111/j.1439-0507.2010.01885.x
Abstract
Sepsis is a leading cause of death in the intensive care unit (ICU), with Candida spp. in the forefront among the important pathogens. As recent studies have shown, survival outcome is strongly influenced by adequate antifungal therapy at an early stage that is often delayed by the time lag associated with microbiological diagnosis. Risk factor-based prediction models have a high negative predictive value, but positive prediction of candidaemia in the individual patient remains elusive. New antigen- or DNA-based methods for early diagnosis still await clinical validation. Their routine use is hampered by methodological issues. Species distribution of invasive Candida isolates in the ICU appears to be influenced primarily by age, previous hospitalisation and colonising species. In the context of the importance of adequate first-line treatment, recent guidelines favour the use of echinocandins in critically ill patients with symptoms evoking high suspicion of invasive candidiasis. This is supported by robust clinical trial data, a few interactions and low toxicity. Fluconazole is characterised by reduced activity against some important Candida species, elevated rates of persistent infection seen in comparative trials. Amphotericin B deoxycholate should be considered obsolete in ICU patients because of its high toxicity. Invasive aspergillosis (IA) is a rare devastating infection in the general ICU population, but some centres have reported elevated incidences and underdiagnosis as determined in autopsy-controlled studies. Treatment with mould-active agents such as voriconazole must be initiated early in patients with suspected IA.Keywords
This publication has 79 references indexed in Scilit:
- Effect of Antifungal Therapy Timing on Mortality in Cancer Patients with CandidemiaAntimicrobial Agents and Chemotherapy, 2010
- Time to positive culture and identification for Candida blood stream infectionsDiagnostic Microbiology and Infectious Disease, 2009
- Epidemiology of candidemia in intensive care unitsInternational Journal of Antimicrobial Agents, 2008
- Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia TreatmentAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Activity of Anidulafungin against Candida albicans BiofilmsAntimicrobial Agents and Chemotherapy, 2008
- A Prospective Clinical Trial of a Real-Time Polymerase Chain Reaction Assay for the Diagnosis of Candidemia in Nonneutropenic, Critically Ill AdultsClinical Infectious Diseases, 2008
- Acute kidney injury in intensive care unit patients: a comparison between the RIFLE and the Acute Kidney Injury Network classificationsCritical Care, 2008
- Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion TestingJournal of Clinical Microbiology, 2007
- Epidemiology of Invasive Candidiasis: a Persistent Public Health ProblemClinical Microbiology Reviews, 2007
- Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated CandidiasisAntimicrobial Agents and Chemotherapy, 2007